New York, December 20, 2023 – Clinical-stage biotechnology company, Lipella Pharmaceuticals (Nasdaq: LIPO) is celebrating a year of strategic accomplishments on its first anniversary as a public company. Lipella is advancing three clinical indications and has been granted two Orphan Drug Designations by the US Food and Drug Administration (FDA). Today, the company announced it has successfully completed a … Continue reading PRISM MarketView: Biotech In Motion – Lipella Pharmaceuticals Celebrates Year of Success